Cargando…

Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib

BACKGROUND: Chemoresistance often limits the success of the pharmacological treatment in acute myeloid leukemia (AML) patients. Although positive results have been obtained with tyrosine kinase inhibitors (TKIs), such as sorafenib, especially in patients with Fms-like tyrosine kinase 3 (FLT3)-positi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macias, Rocio I.R., Sánchez-Martín, Anabel, Rodríguez-Macías, Gabriela, Sánchez-Abarca, Luis I., Lozano, Elisa, Herraez, Elisa, Odero, Maria D., Díez-Martín, José L., Marin, Jose J.G., Briz, Oscar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033373/ https://www.ncbi.nlm.nih.gov/pubmed/29983874 http://dx.doi.org/10.18632/oncotarget.25494

Ejemplares similares

Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1
por: Herraez, Elisa, et al.
Publicado: (2017)

Models for Understanding Resistance to Chemotherapy in Liver Cancer
por: Marin, Jose J. G., et al.
Publicado: (2019)

Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition
por: Lozano, Elisa, et al.
Publicado: (2018)

Plasma Membrane Transporters as Biomarkers and Molecular Targets in Cholangiocarcinoma
por: Marin, Jose J.G., et al.
Publicado: (2020)

Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma
por: Marin, Jose J. G., et al.
Publicado: (2020)

Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment
por: Marin, Jose J.G., et al.
Publicado: (2020)

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
por: Rodríguez-Macías, Gabriela, et al.
Publicado: (2023)

Mechanisms of Anticancer Drug Resistance in Hepatoblastoma
por: Marin, Jose J. G., et al.
Publicado: (2019)

The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy
por: Marin, Jose JG, et al.
Publicado: (2014)

Molecular Bases of Drug Resistance in Hepatocellular Carcinoma
por: Marin, Jose J.G., et al.
Publicado: (2020)

The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma
por: Geier, Andreas, et al.
Publicado: (2017)

Role of the Plasma Membrane Transporter of Organic Cations OCT1 and Its Genetic Variants in Modern Liver Pharmacology
por: Lozano, Elisa, et al.
Publicado: (2013)

Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers
por: Marin, Jose J. G., et al.
Publicado: (2022)

Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity
por: Lozano, Elisa, et al.
Publicado: (2023)

Vertigo as the First Sign of Chronic Myeloid Leukemia: A Case Report and Literature Review
por: Martín-Hernández, Rubén, et al.
Publicado: (2013)

Role of Genetic Variations in the Hepatic Handling of Drugs
por: Marin, Jose J. G., et al.
Publicado: (2020)

A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma
por: Macias, Rocio I.R., et al.
Publicado: (2020)

Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics
por: Macias, Rocio I.R., et al.
Publicado: (2021)

The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias
por: Pippa, Raffaella, et al.
Publicado: (2020)

Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia
por: Alarcón-Payer, Carolina, et al.
Publicado: (2022)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia
por: Arriazu, Elena, et al.
Publicado: (2016)

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
por: Halbach, Sebastian, et al.
Publicado: (2016)

Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure‐FLT3 Relationship
por: Liu, Tao, et al.
Publicado: (2018)

Spontaneous Remission of Acute Myeloid Leukemia: A Case Report
por: Martínez-Díez, Yolanda, et al.
Publicado: (2022)

Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: “Doublet Technology”
por: García-Guerrero, Estefanía, et al.
Publicado: (2018)

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma
por: Alonso-Peña, Marta, et al.
Publicado: (2019)

Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis
por: Brodie, Rachel, et al.
Publicado: (2019)

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations
por: Daver, Naval, et al.
Publicado: (2020)

The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia
por: García-Tuñón, Ignacio, et al.
Publicado: (2017)

Impact of Alternative Splicing Variants on Liver Cancer Biology
por: Marin, Jose J. G., et al.
Publicado: (2021)

Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives
por: Macias, Rocio I. R.
Publicado: (2014)

Anti-Vascular Endothelial Growth Factor Effects of Sorafenib and Arsenic Trioxide in Acute Myeloid Leukemia Cell Lines
por: Haghi, Atousa, et al.
Publicado: (2017)

Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification
por: Tian, Tian, et al.
Publicado: (2019)

Clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
por: Andrés‐Zayas, Cristina, et al.
Publicado: (2021)

Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current
por: Hernández-Bule, María Luisa, et al.
Publicado: (2021)

Future Approaches for Treating Chronic Myeloid Leukemia: CRISPR Therapy
por: Vuelta, Elena, et al.
Publicado: (2021)

Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance
por: Marin, Jose J. G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b7e993j5tn6r37mhto92trul15